Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimization of Albuminuria-Lowering Therapies for Individual Patients with Type 2 Diabetes Using Empagliflozin and Finerenone in a Pilot Remote Clinical Trial
2023-508585-15-00Phase 4Completed
- Sponsor
- University Medical Center Groningen
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of empagliflozin and finerenone in type 2 diabetes mellitus (T2DM), albuminuria and chronic kidney disease (CKD), sponsored by University Medical Center Groningen. Primary endpoints: Participants’ perspectives toward the feasibility of participation in a trial at home with digital technologies, Urine collection completeness and analyzability and 2 more. Started Jul 2024; status: completed.
02
Drugs
empagliflozinfinerenone
03
Conditions
type 2 diabetes mellitus (T2DM)albuminuriachronic kidney disease (CKD)
Beyond the preview
Go deeper on 2023-508585-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508585-15-00.